Review




Structured Review

Human Protein Atlas nfix gene
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Nfix Gene, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nfix gene/product/Human Protein Atlas
Average 86 stars, based on 1 article reviews
nfix gene - by Bioz Stars, 2026-06
86/100 stars

Images

1) Product Images from "Mechanistic Insights Into NFIX‐Mediated DNA Recognition and Transcriptional Regulation in Skeletal Muscle"

Article Title: Mechanistic Insights Into NFIX‐Mediated DNA Recognition and Transcriptional Regulation in Skeletal Muscle

Journal: Smart Medicine

doi: 10.1002/smmd.70027

NFIX regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) Single‐cell RNA‐seq analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Figure Legend Snippet: NFIX regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) Single‐cell RNA‐seq analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.

Techniques Used: Binding Assay, RNA Sequencing, Expressing, Knockdown, Western Blot, DNA Synthesis, Control, TUNEL Assay, Single Vesicle Fusion Assay

NFIX‐mediated transcriptional regulation in human skeletal muscle cells. (A) Volcano plot showing differentially expressed genes (DEGs) in NFIX knockdown versus control human skeletal muscle cells, as determined by RNA‐seq. Significantly upregulated (red) and downregulated (blue) genes are indicated. (B) KEGG pathway enrichment analysis of DEGs, highlighting significant enrichment in immune and inflammatory responses, metabolic processes, and stress‐related pathways. (C) Heat map illustrating expression changes of representative NFIX‐regulated genes across enriched pathways. (D) qPCR validation of NMNAT2, PPARD, IL1RN, IL6, NDRG2, and EGR1. Data in (D) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Figure Legend Snippet: NFIX‐mediated transcriptional regulation in human skeletal muscle cells. (A) Volcano plot showing differentially expressed genes (DEGs) in NFIX knockdown versus control human skeletal muscle cells, as determined by RNA‐seq. Significantly upregulated (red) and downregulated (blue) genes are indicated. (B) KEGG pathway enrichment analysis of DEGs, highlighting significant enrichment in immune and inflammatory responses, metabolic processes, and stress‐related pathways. (C) Heat map illustrating expression changes of representative NFIX‐regulated genes across enriched pathways. (D) qPCR validation of NMNAT2, PPARD, IL1RN, IL6, NDRG2, and EGR1. Data in (D) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.

Techniques Used: Knockdown, Control, RNA Sequencing, Expressing, Biomarker Discovery

Structural basis of sequence‐specific DNA recognition by NFIX. (A) Detailed interactions of the NFIX DBD :dsDNA interface. NFIX DBD is shown as a ribbon with a semitransparent surface; the duplex is contoured with a composite‐omit 2m F o –D F c electron density map contoured at 2 σ . Insets highlight base‐specific contacts and phosphate‐backbone interactions formed by key residues. (B) Schematic diagram summarizing the protein–DNA contacts observed in the NFIX DBD :dsDNA structure. (C) Electrostatic potential surface of NFIX DBD at the DNA interface, illustrating the basic patch complementary to the DNA backbone. (D) Model of a hypothetical 2:1 NFIX DBD :dsDNA assembly generated by aligning two NFIX molecules to the symmetric half‐sites. Extensive steric clashes (indicated) argue against simultaneous dimeric occupancy of the palindromic motif on short B‐form dsDNA. (E) Model of a hypothetical NFIX dimer on nucleosomal chromatin at a dyad motif. Bending of nucleosomal DNA permits simultaneous binding of two NFIX molecules.
Figure Legend Snippet: Structural basis of sequence‐specific DNA recognition by NFIX. (A) Detailed interactions of the NFIX DBD :dsDNA interface. NFIX DBD is shown as a ribbon with a semitransparent surface; the duplex is contoured with a composite‐omit 2m F o –D F c electron density map contoured at 2 σ . Insets highlight base‐specific contacts and phosphate‐backbone interactions formed by key residues. (B) Schematic diagram summarizing the protein–DNA contacts observed in the NFIX DBD :dsDNA structure. (C) Electrostatic potential surface of NFIX DBD at the DNA interface, illustrating the basic patch complementary to the DNA backbone. (D) Model of a hypothetical 2:1 NFIX DBD :dsDNA assembly generated by aligning two NFIX molecules to the symmetric half‐sites. Extensive steric clashes (indicated) argue against simultaneous dimeric occupancy of the palindromic motif on short B‐form dsDNA. (E) Model of a hypothetical NFIX dimer on nucleosomal chromatin at a dyad motif. Bending of nucleosomal DNA permits simultaneous binding of two NFIX molecules.

Techniques Used: Sequencing, Generated, Binding Assay

NFIX activates skeletal muscle–related promoters via specific DNA recognition. (A) Mutational analysis of sequence‐recognition residues in NFIX DBD using BLI, comparing the dsDNA binding profiles of wild‐type NFIX DBD with R116A, K125A, and R116A/K125A mutants. (B) Quantification of relative DNA‐binding affinities, calculated as WT K D ÷ mutant K D × 100. (C–F) Dual‐luciferase assays with pGL3 reporters driven by the NDRG2 , EGR1 , IL1RN , and NMNAT2 promoters. WT NFIX robustly enhances reporter activity, whereas the DNA‐binding–defective double mutant (R116A/K125A) fails to activate transcription. Data are mean ± s.d. from ≥ 3 independent experiments; unpaired two‐tailed t ‐test: *** p < 0.001.
Figure Legend Snippet: NFIX activates skeletal muscle–related promoters via specific DNA recognition. (A) Mutational analysis of sequence‐recognition residues in NFIX DBD using BLI, comparing the dsDNA binding profiles of wild‐type NFIX DBD with R116A, K125A, and R116A/K125A mutants. (B) Quantification of relative DNA‐binding affinities, calculated as WT K D ÷ mutant K D × 100. (C–F) Dual‐luciferase assays with pGL3 reporters driven by the NDRG2 , EGR1 , IL1RN , and NMNAT2 promoters. WT NFIX robustly enhances reporter activity, whereas the DNA‐binding–defective double mutant (R116A/K125A) fails to activate transcription. Data are mean ± s.d. from ≥ 3 independent experiments; unpaired two‐tailed t ‐test: *** p < 0.001.

Techniques Used: Sequencing, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Two Tailed Test



Similar Products

94
Thermo Fisher gene exp nfix mm01247488 m1
Gene Exp Nfix Mm01247488 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nfix mm01247488 m1/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
gene exp nfix mm01247488 m1 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

86
Human Protein Atlas nfix gene
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Nfix Gene, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nfix gene/product/Human Protein Atlas
Average 86 stars, based on 1 article reviews
nfix gene - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

87
Thermo Fisher gene exp nfix mm00477791 m1
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Gene Exp Nfix Mm00477791 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 87/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nfix mm00477791 m1/product/Thermo Fisher
Average 87 stars, based on 1 article reviews
gene exp nfix mm00477791 m1 - by Bioz Stars, 2026-06
87/100 stars
  Buy from Supplier

92
Thermo Fisher gene exp nfix hs00958846 m1
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Gene Exp Nfix Hs00958846 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nfix hs00958846 m1/product/Thermo Fisher
Average 92 stars, based on 1 article reviews
gene exp nfix hs00958846 m1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

92
Thermo Fisher gene exp nfix hs00958843 m1
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Gene Exp Nfix Hs00958843 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nfix hs00958843 m1/product/Thermo Fisher
Average 92 stars, based on 1 article reviews
gene exp nfix hs00958843 m1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

90
Angelini Pharma nfix gene
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Nfix Gene, supplied by Angelini Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nfix gene/product/Angelini Pharma
Average 90 stars, based on 1 article reviews
nfix gene - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Takeda nfix gene
<t>NFIX</t> regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) <t>Single‐cell</t> <t>RNA‐seq</t> analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.
Nfix Gene, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nfix gene/product/Takeda
Average 90 stars, based on 1 article reviews
nfix gene - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


NFIX regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) Single‐cell RNA‐seq analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.

Journal: Smart Medicine

Article Title: Mechanistic Insights Into NFIX‐Mediated DNA Recognition and Transcriptional Regulation in Skeletal Muscle

doi: 10.1002/smmd.70027

Figure Lengend Snippet: NFIX regulates skeletal muscle cell proliferation, apoptosis, and differentiation. (A) Schematic diagram illustrating the domain architecture of full‐length human NFIX (residues 1–502) and its DNA‐binding domain. (B) Single‐cell RNA‐seq analysis showing NFIX expression across various human cell types. (C) NFIX expression in skeletal muscle tissues from patients with Duchenne muscular dystrophy (DMD), inclusion body myositis (IBM), nemaline myopathy (NM), polymyositis (PM), and tibial muscular dystrophy (TMD) compared with healthy controls, based on multiple GEO datasets. (D–E) siRNA‐mediated knockdown of NFIX in immortalized human skeletal muscle cells, with depletion efficiency validated by qPCR (D) and Western blot analysis (E). (F, I) EdU incorporation assay showing reduced DNA synthesis in NFIX‐depleted cells compared with control cells (F), quantified as the percentage of EdU‐positive nuclei (I). Scale bar, 100 μm. (G, J) TUNEL assay indicating increased apoptosis in NFIX knockdown cells (G), with quantification of apoptotic nuclei (J). Scale bar, 100 μm. (H, K) Myogenic fusion assay showing reduced myotube formation in NFIX‐deficient cells (H), quantified as fusion index (K). Scale bar, 100 μm. Data in (D–K) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.

Article Snippet: The single‐cell RNA sequencing data for the NFIX gene were obtained from the Human Protein Atlas (HPA) single‐cell database (gene ID: ENSG00000008441).

Techniques: Binding Assay, RNA Sequencing, Expressing, Knockdown, Western Blot, DNA Synthesis, Control, TUNEL Assay, Single Vesicle Fusion Assay

NFIX‐mediated transcriptional regulation in human skeletal muscle cells. (A) Volcano plot showing differentially expressed genes (DEGs) in NFIX knockdown versus control human skeletal muscle cells, as determined by RNA‐seq. Significantly upregulated (red) and downregulated (blue) genes are indicated. (B) KEGG pathway enrichment analysis of DEGs, highlighting significant enrichment in immune and inflammatory responses, metabolic processes, and stress‐related pathways. (C) Heat map illustrating expression changes of representative NFIX‐regulated genes across enriched pathways. (D) qPCR validation of NMNAT2, PPARD, IL1RN, IL6, NDRG2, and EGR1. Data in (D) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.

Journal: Smart Medicine

Article Title: Mechanistic Insights Into NFIX‐Mediated DNA Recognition and Transcriptional Regulation in Skeletal Muscle

doi: 10.1002/smmd.70027

Figure Lengend Snippet: NFIX‐mediated transcriptional regulation in human skeletal muscle cells. (A) Volcano plot showing differentially expressed genes (DEGs) in NFIX knockdown versus control human skeletal muscle cells, as determined by RNA‐seq. Significantly upregulated (red) and downregulated (blue) genes are indicated. (B) KEGG pathway enrichment analysis of DEGs, highlighting significant enrichment in immune and inflammatory responses, metabolic processes, and stress‐related pathways. (C) Heat map illustrating expression changes of representative NFIX‐regulated genes across enriched pathways. (D) qPCR validation of NMNAT2, PPARD, IL1RN, IL6, NDRG2, and EGR1. Data in (D) are presented as mean ± SD, dots represent individual samples. Analysis by unpaired Student's t ‐test. For all panels, n = 3. * p < 0.05.

Article Snippet: The single‐cell RNA sequencing data for the NFIX gene were obtained from the Human Protein Atlas (HPA) single‐cell database (gene ID: ENSG00000008441).

Techniques: Knockdown, Control, RNA Sequencing, Expressing, Biomarker Discovery

Structural basis of sequence‐specific DNA recognition by NFIX. (A) Detailed interactions of the NFIX DBD :dsDNA interface. NFIX DBD is shown as a ribbon with a semitransparent surface; the duplex is contoured with a composite‐omit 2m F o –D F c electron density map contoured at 2 σ . Insets highlight base‐specific contacts and phosphate‐backbone interactions formed by key residues. (B) Schematic diagram summarizing the protein–DNA contacts observed in the NFIX DBD :dsDNA structure. (C) Electrostatic potential surface of NFIX DBD at the DNA interface, illustrating the basic patch complementary to the DNA backbone. (D) Model of a hypothetical 2:1 NFIX DBD :dsDNA assembly generated by aligning two NFIX molecules to the symmetric half‐sites. Extensive steric clashes (indicated) argue against simultaneous dimeric occupancy of the palindromic motif on short B‐form dsDNA. (E) Model of a hypothetical NFIX dimer on nucleosomal chromatin at a dyad motif. Bending of nucleosomal DNA permits simultaneous binding of two NFIX molecules.

Journal: Smart Medicine

Article Title: Mechanistic Insights Into NFIX‐Mediated DNA Recognition and Transcriptional Regulation in Skeletal Muscle

doi: 10.1002/smmd.70027

Figure Lengend Snippet: Structural basis of sequence‐specific DNA recognition by NFIX. (A) Detailed interactions of the NFIX DBD :dsDNA interface. NFIX DBD is shown as a ribbon with a semitransparent surface; the duplex is contoured with a composite‐omit 2m F o –D F c electron density map contoured at 2 σ . Insets highlight base‐specific contacts and phosphate‐backbone interactions formed by key residues. (B) Schematic diagram summarizing the protein–DNA contacts observed in the NFIX DBD :dsDNA structure. (C) Electrostatic potential surface of NFIX DBD at the DNA interface, illustrating the basic patch complementary to the DNA backbone. (D) Model of a hypothetical 2:1 NFIX DBD :dsDNA assembly generated by aligning two NFIX molecules to the symmetric half‐sites. Extensive steric clashes (indicated) argue against simultaneous dimeric occupancy of the palindromic motif on short B‐form dsDNA. (E) Model of a hypothetical NFIX dimer on nucleosomal chromatin at a dyad motif. Bending of nucleosomal DNA permits simultaneous binding of two NFIX molecules.

Article Snippet: The single‐cell RNA sequencing data for the NFIX gene were obtained from the Human Protein Atlas (HPA) single‐cell database (gene ID: ENSG00000008441).

Techniques: Sequencing, Generated, Binding Assay

NFIX activates skeletal muscle–related promoters via specific DNA recognition. (A) Mutational analysis of sequence‐recognition residues in NFIX DBD using BLI, comparing the dsDNA binding profiles of wild‐type NFIX DBD with R116A, K125A, and R116A/K125A mutants. (B) Quantification of relative DNA‐binding affinities, calculated as WT K D ÷ mutant K D × 100. (C–F) Dual‐luciferase assays with pGL3 reporters driven by the NDRG2 , EGR1 , IL1RN , and NMNAT2 promoters. WT NFIX robustly enhances reporter activity, whereas the DNA‐binding–defective double mutant (R116A/K125A) fails to activate transcription. Data are mean ± s.d. from ≥ 3 independent experiments; unpaired two‐tailed t ‐test: *** p < 0.001.

Journal: Smart Medicine

Article Title: Mechanistic Insights Into NFIX‐Mediated DNA Recognition and Transcriptional Regulation in Skeletal Muscle

doi: 10.1002/smmd.70027

Figure Lengend Snippet: NFIX activates skeletal muscle–related promoters via specific DNA recognition. (A) Mutational analysis of sequence‐recognition residues in NFIX DBD using BLI, comparing the dsDNA binding profiles of wild‐type NFIX DBD with R116A, K125A, and R116A/K125A mutants. (B) Quantification of relative DNA‐binding affinities, calculated as WT K D ÷ mutant K D × 100. (C–F) Dual‐luciferase assays with pGL3 reporters driven by the NDRG2 , EGR1 , IL1RN , and NMNAT2 promoters. WT NFIX robustly enhances reporter activity, whereas the DNA‐binding–defective double mutant (R116A/K125A) fails to activate transcription. Data are mean ± s.d. from ≥ 3 independent experiments; unpaired two‐tailed t ‐test: *** p < 0.001.

Article Snippet: The single‐cell RNA sequencing data for the NFIX gene were obtained from the Human Protein Atlas (HPA) single‐cell database (gene ID: ENSG00000008441).

Techniques: Sequencing, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Two Tailed Test